Evommune, Inc. Operating Lease Cost
Evommune, Inc. (EVMN) reported Operating Lease Cost of $793.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- Evommune, Inc. operating lease, cost for the quarter ending 2026-06-30 was $538.00K, a 158.65% increase year-over-year.
- Evommune, Inc. operating lease, cost for the quarter ending 2026-03-31 was $255.00K, a 22.60% increase year-over-year.
- Evommune, Inc. operating lease, cost for the quarter ending 2025-12-31 was $224.00K, a 16.73% decline year-over-year.
- Evommune, Inc. operating lease, cost for the quarter ending 2025-09-30 was $177.00K.
- Evommune, Inc. operating lease, cost for fiscal 2025 was $817.00K, a 1.80% decline from fiscal 2024.
- Evommune, Inc. operating lease, cost for fiscal 2024 was $832.00K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $538.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $793.00K 10-Q · filed 2026-08-06 | $1.02M derived: sum of 3 quarters · filed 2026-08-06 | $1.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $255.00K 10-Q · filed 2026-05-07 | $479.00K derived: sum of 2 quarters · filed 2026-05-07 | $656.00K derived: sum of 3 quarters · filed 2026-05-07 | $864.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $224.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $401.00K derived: sum of 2 quarters · filed 2026-03-05 | $609.00K derived: sum of 3 quarters · filed 2026-08-06 | $817.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $177.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-12-11 | $385.00K derived: sum of 2 quarters · filed 2026-08-06 | $593.00K 10-Q · filed 2025-12-11 | $862.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $208.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $416.00K 10-Q · filed 2026-08-06 | $685.00K derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-03-31 | $208.00K 10-Q · filed 2026-05-07 | $477.00K derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $269.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $832.00K 10-K · filed 2026-03-05 | ||
| 2024-09-30 | $563.00K 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |